

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Rofecoxib

Item No. 10010260

CAS Registry No.: 162011-90-7

Formal Name: 4-[4-(methylsulfonyl)phenyl]-3-phenyl-

2(5H)-furanone

Synonym: MK-966 MF: $C_{17}H_{14}O_4S$ FW: 314.4 **Purity:** ≥98% UV/Vis.: λ_{max} : 284 nm

Supplied as: A crystalline solid

Storage: -20°C Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Rofecoxib is supplied as a crystalline solid. A stock solution may be made by dissolving the rofecoxib in the solvent of choice, which should be purged with an inert gas. Rofecoxib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of rofecoxib in ethanol is approximately 0.1 mg/ml and approximately 25 mg/ml in DMSO and DMF.

Description

Rofecoxib is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2 over COX-1 with IC₅₀ values of 0.018 and >15 µM, respectively, for production of prostaglandin E₂ (PGE₂; Item No. 14010) in CHO cells expressing the recombinant human enzymes. In vivo, rofecoxib inhibits carrageenan-induced paw edema and hyperalgesia ($ID_{50}s = 1.5$ and 1.0 mg/kg, respectively), LPS-induced pyresis (ID₅₀ = 0.24 mg/kg), and M. butyricum-induced arthritis (ID₅₀ = 0.74 mg/kg/day per day) in rats. Formulations containing rofecoxib were previously used in the treatment of pain and arthritis.

Reference

1. Chan, C.C., Boyce, S., Brideau, C., et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. 290(2), 551-560 (1999).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the material can be found on our website.

Copyright Cayman Chemical Company, 10/29/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM